Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the "Breakthrough Therapy Designation Drug" by the Center for Drug Evaluation (CDE) and currently enter a phase III clinical trial for treatment of patients with small cell lung cancer (SCLC) with disease progression or recurrence after two lines of prior systematic chemotherapy. Chiauranib is a new chemical entity designed and developed independently by Chipscreen, with global patent protection. Chiauranib selectively inhibits multiple kinase targets such as aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit, thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy through multi-pathway mechanisms.Targeting abnormal Aurora B signaling pathway in SCLC is one of efficacy basis of Chiauranib monotherapy and also an important mechanistic difference between it and other anti-angiogenic therapies. Chiauranib obtained Phase I clinical trial approval from the former China Food and Drug Administration (CFDA) in August 2013, and completed multiple Phase II clinical trials with monotherapy or combined therapy for different types of malignant tumors in China, showing positive clinical efficacy and well tolerance in tumor patients. In addition, a Pre-IND communication with the FDA for clinical trial of Chiauranib against SCLC in US has been conducted. SCLC accounts for about 15-20% of total lung cancer patients. In contrast to non-small cell lung cancer, SCLC urgently requires new therapeutic mechanisms due to a lack of identified tumor driver genes and corresponding targeted therapeutics. Treatment is dominated by chemoradiotherapy, characterized by short-term efficacy but frequent relapse, making the long-term survival rate far less than that of non-small cell lung cancer. In preliminary clinical trials on patients with multiline treatment failure, Chiauranib obtained encouraging efficcay as monotherapy by comparing with the historical control data, which may bring a better treatment option for SCLC patients.